Meningitis-Pipeline Review, H1 2016

Meningitis-Pipeline Review, H1 2016

  • Products Id :- GMDHC8202IDB
  • |
  • Pages: 63
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Meningitis-Pipeline Review, H1 2016


Global Markets Direct's, 'Meningitis-Pipeline Review, H1 2016', provides an overview of the Meningitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Meningitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Meningitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Meningitis

The report reviews pipeline therapeutics for Meningitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Meningitis therapeutics and enlists all their major and minor projects

The report assesses Meningitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Meningitis

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Meningitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Meningitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Meningitis Overview 8

Therapeutics Development 9

Pipeline Products for Meningitis-Overview 9

Pipeline Products for Meningitis-Comparative Analysis 10

Meningitis-Therapeutics under Development by Companies 11

Meningitis-Therapeutics under Investigation by Universities/Institutes 12

Meningitis-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Meningitis-Products under Development by Companies 16

Meningitis-Products under Investigation by Universities/Institutes 17

Meningitis-Companies Involved in Therapeutics Development 18

Adenium Biotech ApS 18

Amplyx Pharmaceuticals, Inc. 19

Chiesi Farmaceutici SpA 20

ContraFect Corporation 21

Genticel S.A. 22

LG Life Science LTD. 23

Matinas BioPharma Holdings, Inc. 24

Sanofi Pasteur SA 25

Viamet Pharmaceuticals, Inc. 26

Meningitis-Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

amphotericin B-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

AP-114-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

CF-302-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

CF-303-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

CF-305-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

CF-309-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Eupenta-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

LBVD-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

meningitis vaccine-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

meropenem-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

pneumococcal [serotype 4, 6A] vaccine-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Small Molecules to Inhibit Pkh2-02 for Cryptococcal Meningitis-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Streptococcus pneumonia vaccine-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

tuberculous meningitis vaccine-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

viral vaccine-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

VT-1129-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Meningitis-Dormant Projects 54

Meningitis-Discontinued Products 55

Meningitis-Product Development Milestones 56

Featured News & Press Releases 56

Jun 01, 2016: Viamet Receives Fast Track Designation from the FDA for VT-1129 for the Treatment of Cryptococcal Meningitis 56

Sep 16, 2015: FDA Grants QIDP Designation to VT-1129 for Treatment of Cryptococcal Meningitis 56

Apr 24, 2015: Viamet to Provide Update on VT-1129, Novel Antifungal Program at ECCMID 2015 57

Apr 01, 2015: LG Life Sciences Succeeds in Phase 3 International Clinical Trials for 5-in-1 Vaccine Eupenta 57

Sep 11, 2014: Viamet Receives Orphan Drug Designation for VT-1129 58

Oct 25, 2010: Phase III data show that Novartis meningococcal vaccine Menveo demonstrated robust immunogenicity in infants 58

Jun 08, 2010: Novartis receives Health Canada approval of Menveo to prevent meningococcal disease 58

Mar 18, 2010: Novartis receives approval in the European Union for Menveo, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease 59

Feb 22, 2010: Novartis receives FDA approval of Menveo, a vaccine to prevent meningococcal disease 59

Jun 30, 2009: Novartis receives Complete Response letter from the US Food and Drug Administration for its investigational vaccine Menveo 60

May 06, 2008: Novartis Menveo vaccine shows superior immune response against four types of meningitis disease in pivotal phase III trial 60

Jan 09, 2008: New data show Menveo to be the first quadrivalent meningococcal vaccine to provide immunogenicity in infants 60

Nov 15, 2007: New data for Menveo vaccine show excellent immune response and broad protection for infants against meningococcal meningitis 61

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Figures

Number of Products under Development for Meningitis, H1 2016 9

Number of Products under Development for Meningitis-Comparative Analysis, H1 2016 10

Number of Products under Development by Companies, H1 2016 11

Comparative Analysis by Clinical Stage Development, H1 2016 14

Comparative Analysis by Early Stage Products, H1 2016 15

Assessment by Monotherapy Products, H1 2016 27

Number of Products by Targets, H1 2016 28

Number of Products by Stage and Targets, H1 2016 28

Number of Products by Mechanism of Actions, H1 2016 30

Number of Products by Stage and Mechanism of Actions, H1 2016 30

Number of Products by Routes of Administration, H1 2016 32

Number of Products by Stage and Routes of Administration, H1 2016 32

Number of Products by Molecule Types, H1 2016 34

Number of Products by Stage and Top 10 Molecule Types, H1 2016 34

List of Tables

Number of Products under Development for Meningitis, H1 2016 9

Number of Products under Development for Meningitis-Comparative Analysis, H1 2016 10

Number of Products under Development by Companies, H1 2016 11

Number of Products under Investigation by Universities/Institutes, H1 2016 12

Comparative Analysis by Late Stage Development, H1 2016 13

Comparative Analysis by Clinical Stage Development, H1 2016 14

Comparative Analysis by Early Stage Development, H1 2016 15

Products under Development by Companies, H1 2016 16

Products under Investigation by Universities/Institutes, H1 2016 17

Meningitis-Pipeline by Adenium Biotech ApS, H1 2016 18

Meningitis-Pipeline by Amplyx Pharmaceuticals, Inc., H1 2016 19

Meningitis-Pipeline by Chiesi Farmaceutici SpA, H1 2016 20

Meningitis-Pipeline by ContraFect Corporation, H1 2016 21

Meningitis-Pipeline by Genticel S.A., H1 2016 22

Meningitis-Pipeline by LG Life Science LTD., H1 2016 23

Meningitis-Pipeline by Matinas BioPharma Holdings, Inc. , H1 2016 24

Meningitis-Pipeline by Sanofi Pasteur SA, H1 2016 25

Meningitis-Pipeline by Viamet Pharmaceuticals, Inc., H1 2016 26

Assessment by Monotherapy Products, H1 2016 27

Number of Products by Stage and Target, H1 2016 29

Number of Products by Stage and Mechanism of Action, H1 2016 31

Number of Products by Stage and Route of Administration, H1 2016 33

Number of Products by Stage and Molecule Type, H1 2016 35

Meningitis-Dormant Projects, H1 2016 54

Meningitis-Discontinued Products, H1 2016 55

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Adenium Biotech ApS

Amplyx Pharmaceuticals, Inc.

Chiesi Farmaceutici SpA

ContraFect Corporation

Genticel S.A.

LG Life Science LTD.

Matinas BioPharma Holdings, Inc.

Sanofi Pasteur SA

Viamet Pharmaceuticals, Inc.

Meningitis Therapeutic Products under Development, Key Players in Meningitis Therapeutics, Meningitis Pipeline Overview, Meningitis Pipeline, Meningitis Pipeline Assessment

select a license
Single User License
USD 2000 INR 147300
Site License
USD 4000 INR 294600
Corporate User License
USD 6000 INR 441900



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]